NY-BEHAVOX
20.10.2020 14:02:09 CEST | Business Wire | Press release
Behavox , the world’s only AI-based data operating platform used by firms to catch misconduct before it causes massive regulatory fines and company crises, today announced that Danske Bank A/S , Denmark’s largest, full-service bank, has successfully implemented Behavox’s solution in less than five months for compliance supervision.
"Danske Bank is committed to developing innovative solutions to help us reach the highest standards of corporate governance and meet the expectations of our customers, employees and other stakeholders," said Simon Kingsbury, Executive Vice President at Danske Bank. “By partnering with Behavox, we have been able to significantly advance our capabilities in compliance. By using the artificial intelligence and machine learning of Behavox we are able to rapidly identify potentially non-compliant activity and take appropriate action."
Behavox has vast customer experience successfully implementing the largest, most complex projects in the financial services sector – from the world’s biggest multinational banks to the most prominent hedge funds and private equity firms. Danske Bank represents one of the larger projects Behavox has implemented, making the four-month SaaS-based deployment a major achievement for the customer and company alike.
In June, Danske Bank partnered with Behavox to establish group wide compliance communications monitoring, and has since completed a seamless, full SaaS implementation of the Behavox Compliance solution. The Behavox Compliance solution is helping the bank become faster, smarter, and more agile in supporting its employees as they work for the bank’s millions of customers throughout the Nordics and beyond.
“As the future of the workplace is likely to remain increasingly distributed, Danske Bank needs an agile compliance solution that allows them to strengthen regulatory compliance controls in their mission to modernize banking," said Nabeel Ebrahim, Chief Revenue Officer at Behavox. “As one of our largest European customers, Behavox is proud to have delivered a regulatory compliance solution that allows Danske Bank to aggregate, analyze, and act on their entire organization's data to help them uphold their risk management commitments."
The ability for Behavox’s solution to provide multilingual (data privacy compliant) coverage of compliance requirements across numerous voice and text-based applications in multiple markets is critical for Danske Bank as well as other leading international firms. Behavox supports financial regulatory compliance requirements for Dodd-Frank, MAR, FCPA, SMR, and MiFID II, and its solutions meet the requirements of the most demanding global regulators, such as FINRA, CFTC, and FCA.
About Behavox Ltd.
Behavox is the gold standard for enterprise risk and compliance solutions. Its AI-powered technology helps global banks, hedge funds, and private equity firms identify bad actors quickly and accurately, preventing massive fines and company-debilitating crises. Behavox solutions uncover financial regulatory misconduct like insider trading, collusion, and market manipulation as well as HR-related misconduct, such as racism, sexual harassment, and discrimination. As an award-winning team of innovators and industry experts, Behavox has a reputation for successfully implementing the largest, most complex, global projects in the market. Customers rely on Behavox as an indispensable extension of their teams. They depend on Behavox to protect the integrity of their operations and preserve the trust of their clients. Founded in 2014, Behavox is headquartered in New York City and has offices in Montreal, San Francisco, Seattle, Singapore, Tokyo, London, and Abu Dhabi. More information about the company is available at www.behavox.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom